Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 7;602(7895):148–155. doi: 10.1038/s41586-021-04280-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 2 — a, Representative plots of CoV2-Dex (HLA-A*24:02) staining in healthy donors. b, Percentage of CoV2-Dex⁺ cells in HLA-A*24:02 healthy donors and COVID-19 patients in acute infection and six months and one year after infection. Dots represent independent donors at each timepoint (n = 3 healthy, n = 6 acute, n = 5 six months, n = 3 one year). Gray lines connect individual donors sampled at different timepoints. c, Percentage of CoV2-Dex⁺ cells in HLA-A*01:01 and HLA-A*11:01 in acute infection and six months and one year after infection (HLA-A*01:01 n = 26 and HLA-A*11:01 n = 10 acute, HLA-A*01:01 n = 21 and HLA-A*11:01 n = 9 six months, HLA-A*01:01 n = 20 and HLA-A*11:01 n = 9 one year). d, Gating strategy for phenotypical analysis of CoV2-Dex⁺ compared to CoV2-Dex^– cells. e, Gating strategy for phenotypical analysis of CoV2-Pent⁺ compared to CoV2-Pent^– cells and frequency of Ki-67⁺, HLA-DR⁺ and CD127 levels in CoV2-Pent^– (gray) and CoV2-Pent⁺ (red) cells in acute COVID-19 (n = 7). f, Frequency of Ki-67⁺, HLA-DR⁺, granzyme B⁺, CX3CR1⁺ and CD127⁺ cells in CoV2-Dex⁺ cells in patients with an HLA-A*01:01 versus HLA-A*11:01 allele (HLA-A*01:01 n = 22 and HLA-A*11:01 n = 6) in the acute phase. b, c, and f, P-values were calculated with a Mann-Whitney-Wilcoxon test. e, P-values were calculated with a Wilcoxon signed-rank test. All tests were performed two-sided.